# US 2024/0200047 A1 · Enzymes with ruvc domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200047 A1
- Document ID: US20240200047A1
- Status: Published application
- Kind: A1
- Application number: 18/586,929
- Filed: 2024-02-26
- Published: 2024-06-20
- Earliest claimed: 2021-08-27
- Assignees: Metagenomi, Inc.
- Applicants: Metagenomi, Inc.
- Inventors: Brian C. THOMAS; Christopher BROWN; Rose KANTOR; Audra DEVOTO; Cristina BUTTERFIELD; Lisa ALEXANDER; Daniela S.A. GOLTSMAN; Jason LIU; Rebecca LAMOTHE; Diego ESPINOSA; Meghan STORLIE; Greg COST
- Web page: https://patentgrep.com/patent/US20240200047A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

## Claims

### Claim 1

An engineered nuclease system comprising:
a. an endonuclease or a ribonucleic acid encoding said endonuclease, wherein said endonuclease comprises a sequence having at least 80% sequence identity to SEQ ID NO: 1433; and
b. an engineered guide ribonucleic acid structure configured to form a complex with said endonuclease, said engineered guide ribonucleic acid structure comprising:
i. a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and
ii. a tracr ribonucleic acid sequence configured to bind to said endonuclease;
wherein said guide ribonucleic acid sequence comprises a sequence having at least 80% sequence identity to non-degenerate nucleotides of SEQ ID NO: 11145.

### Claim 2 (depends on 1)

The engineered nuclease system of claim 1, wherein said guide ribonucleic acid sequence comprises a sequence having at least 90% sequence identity to non-degenerate nucleotides of SEQ ID NO: 11145.

### Claim 3 (depends on 2)

The engineered nuclease system of claim 2, wherein said guide ribonucleic acid sequence comprises non-degenerate nucleotides of SEQ ID NO: 11145.

### Claim 4 (depends on 3)

The engineered nuclease system of claim 3, wherein said tracr ribonucleic acid sequence comprises a sequence having at least 80% sequence identity to SEQ ID NO: 11201.

### Claim 5 (depends on 4)

The engineered nuclease system of claim 4, wherein said tracr ribonucleic acid sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO: 11201.

### Claim 6 (depends on 5)

The engineered nuclease system of claim 5, wherein said tracr ribonucleic acid sequence comprises a sequence of SEQ ID NO: 11201.

### Claim 7 (depends on 6)

The engineered nuclease system of claim 6, wherein said engineered guide ribonucleic acid structure comprises:
a. at least two ribonucleic acid polynucleotides; or
b. one ribonucleic acid polynucleotide comprising said guide ribonucleic acid sequence and said tracr ribonucleic acid sequence.

### Claim 8 (depends on 2)

The engineered nuclease system of claim 2, wherein said tracr ribonucleic acid sequence comprises a sequence of SEQ ID NO: 11201.

### Claim 9 (depends on 6)

The engineered nuclease system of claim 6, wherein said endonuclease comprises a sequence having at least 90% sequence identity to SEQ ID NO: 1433.

### Claim 10 (depends on 9)

The engineered nuclease system of claim 9, wherein said endonuclease comprises a sequence of SEQ ID NO: 1433.

### Claim 11 (depends on 6)

The engineered nuclease system of claim 6, wherein said endonuclease comprises a RuvC_III domain, said RuvC_III domain comprising a sequence having at least 80% sequence identity to SEQ ID NO: 3253.

### Claim 12 (depends on 11)

The engineered nuclease system of claim 11, wherein said RuvC_III domain comprises a sequence of SEQ ID NO: 3253.

### Claim 13 (depends on 12)

The engineered nuclease system of claim 12, wherein said endonuclease comprises an HNH domain, wherein said HNH domain comprising a sequence having at least 80% sequence identity to SEQ ID NO: 5068.

### Claim 14 (depends on 13)

The engineered nuclease system of claim 13, said HNH domain comprises a sequence of SEQ ID NO: 5068.

### Claim 15 (depends on 6)

The engineered nuclease system of claim 6, wherein said endonuclease is a class 2, type II Cas endonuclease.

### Claim 16

A method of editing a locus in a cell, said method comprising contacting to said cell:
a. an endonuclease or a ribonucleic acid encoding said endonuclease, wherein said endonuclease comprises a sequence having at least 80% sequence identity to SEQ ID NO: 1433; and
b. an engineered guide ribonucleic acid structure configured to form a complex with said endonuclease, said engineered guide ribonucleic acid structure comprising:
i. a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and
ii. a tracr ribonucleic acid sequence configured to bind to said endonuclease;
wherein said guide ribonucleic acid sequence comprises a sequence having at least 80% sequence identity to non-degenerate nucleotides of SEQ ID NO: 11145.

### Claim 17 (depends on 16)

The method of claim 16, wherein said guide ribonucleic acid sequence comprises a sequence having at least 90% sequence identity to non-degenerate nucleotides of SEQ ID NO: 11145.

### Claim 18 (depends on 17)

The method of claim 17, wherein said guide ribonucleic acid sequence comprises non-degenerate nucleotides of SEQ ID NO: 11145.

### Claim 19 (depends on 18)

The method of claim 18, wherein said tracr ribonucleic acid sequence comprises a sequence having at least 80% sequence identity to SEQ ID NO: 11201.

### Claim 20 (depends on 19)

The method of claim 19, wherein said tracr ribonucleic acid sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO: 11201.

### Claim 21 (depends on 20)

The method of claim 20, wherein said tracr ribonucleic acid sequence comprises a sequence of SEQ ID NO: 11201.

### Claim 22 (depends on 17)

The method of claim 17, wherein said tracr ribonucleic acid sequence comprises a sequence of SEQ ID NO: 11201.

### Claim 23 (depends on 21)

The method of claim 21, wherein said endonuclease comprises a sequence having at least 90% sequence identity to SEQ ID NO: 1433.

### Claim 24 (depends on 23)

The method of claim 23, wherein said endonuclease comprises a sequence of SEQ ID NO: 1433.

### Claim 25 (depends on 21)

The method of claim 21, wherein said endonuclease comprises a RuvC_III domain, said RuvC_III domain comprising a sequence having at least 80% sequence identity to SEQ ID NO: 3253.

### Claim 26 (depends on 25)

The method of claim 25, wherein said RuvC_III domain comprises a sequence of SEQ ID NO: 3253.

### Claim 27 (depends on 26)

The method of claim 26, wherein said endonuclease comprises an HNH domain, said HNH domain comprising a sequence having at least 80% sequence identity to SEQ ID NO: 5068.

### Claim 28 (depends on 27)

The method of claim 27, wherein said HNH domain comprises a sequence of SEQ ID NO: 5068.

### Claim 29 (depends on 21)

The method of claim 21, wherein said endonuclease is a class 2, type II Cas endonuclease.

### Claim 30 (depends on 24)

The method of claim 24, further comprising contacting said cell with a deoxyribonucleic acid repair template.
